The addition of the immunotherapy agent toripalimab (Coherus/Junshi Biosciences) to standard first-line chemotherapy significantly delayed disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma compared with placebo in the phase 3 JUPITER-02 trial.
Nasopharyngeal carcinoma is challenging because it typically is diagnosed in an advanced stage when current therapy options are extremely limited, noted lead investigator Rui-Hua Xu, MD, PhD. The duration of response